AA
CRVS icon

ALPS Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

ALPS Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Buy
85,340
+17,146
+25% +$238K 0.01% 636
2026
Q1 		$998K Buy
68,194
+6,876
+11% +$110K ﹤0.01% 586
2025
Q4 		$472K Buy
+61,318
New +$484K ﹤0.01% 775

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

ALPS Advisors's CRVS Position: Q2 2026 in Review

ALPS Advisors increased its Corvus Pharmaceuticals (CRVS) stake by 25% in Q2 2026, buying an estimated $238K and bringing the position to 85,340 shares worth $1.27M. The position accounts for 0.01% of the portfolio, ranked #636.

ALPS Advisors first reported a position in CRVS in Q4 2025 and has held it in 3 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • ALPS Advisors held 85,340 shares of Corvus Pharmaceuticals worth $1.27M as of Q2 2026.
  • ALPS Advisors bought 17,146 Corvus Pharmaceuticals shares in Q2 2026, an estimated $238K.
  • Corvus Pharmaceuticals made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #636 holding.
  • ALPS Advisors first reported a position in Corvus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.